BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 is a synthetic peptide fifteen amino acids long, derived from a protein in human gastric juice. In rats — overwhelmingly rats — it speeds up healing in tendons ^[6], the gut lining ^[5], and other tissues. The most consistent explanation researchers offer is that it promotes new blood-vessel growth into injured tissue through the VEGFR2 receptor pathway ^[4].

Here is the honest part: almost all of this evidence is in animals. As of a 2025 review, only three small human pilot studies exist, and there are no large controlled trials in people ^[2]. BPC-157 is not approved as a drug anywhere, the FDA placed it in a category not eligible for 503A pharmacy compounding, and it is banned in competitive sport. Common claims about weight loss or muscle building are not in the published evidence. This page describes what the research actually shows — not recommendations, no doses.

What it is

BPC-157 stands for Body Protection Compound 157. It is a stable gastric pentadecapeptide — "pentadecapeptide" means fifteen amino acids, and the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val was drawn from a cytoprotective protein found in gastric juice. Research designations include PL 14736, PLD-116, PL-10, and Bepecin. It is synthesized in the lab, not extracted from any natural source, and has no approved drug form anywhere in the world.

The first human pharmacokinetics: BPC-157 follows linear PK with a very short elimination half-life (under 30 minutes in animal models) and modest bioavailability after intramuscular injection — approximately 14–19% in rats and 45–51% in dogs. It breaks down rapidly into amino-acid fragments that enter normal metabolism ^[3]. A 2025 IV safety pilot in two healthy adults observed no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers at up to 20 mg IV ^[1] — but a sample of two is not safety data in any useful sense.

How it works

The best-characterized mechanism is pro-angiogenic activity via VEGFR2. BPC-157 up-regulates VEGFR2 expression and promotes receptor internalization, activating a VEGFR2-Akt-eNOS (nitric oxide) signaling cascade. Studies in ischemic rat hindlimb muscle and in human vascular endothelial cells showed increased vessel density and faster blood-flow recovery; these effects were blocked when endocytosis was inhibited ^[4]. Additional described pathways include FAK-paxillin signaling (cell migration), sensitization of growth-hormone receptors in tendon fibroblasts, and modulation of dopaminergic and serotonergic systems ^[7].

The brain-gut axis framing — BPC-157 modulating both GI cytoprotection and central neurotransmitter systems — comes from Sikiric and colleagues' body of work ^[7]. Reviewers note that a large share of foundational BPC-157 literature originates from this single group, limiting independent replication ^[2].

What the research shows

Animal repair studies (the bulk of the evidence):

• In Wistar rats, BPC 157 reduced gastric-ulcer area by 45–66% and accelerated glandular-epithelium rebuilding and granulation-tissue formation ^[5].
• In fully transected rat Achilles tendons, BPC 157 improved biomechanical and functional recovery, collagen organization, and tendon integrity versus untreated controls; it also stimulated tendocyte outgrowth in vitro ^[6].
• The angiogenesis mechanism was demonstrated in chick chorioallantoic membrane, rat hindlimb ischemia, and human vascular endothelial cells ^[4].

Pharmacokinetics (rats and dogs, 2022): Linear PK, elimination half-life under 30 minutes, IM bioavailability ~14–51% depending on species, urinary and biliary excretion ^[3].

Human evidence (very limited): A 2025 narrative review concludes that "only three pilot studies have examined BPC-157 in humans" and that "rigorous, large-scale trials are lacking" ^[2]. A 2025 IV safety pilot reported no adverse events in two adults at up to 20 mg IV, but was not designed to test efficacy ^[1]. The human evidence base is too small to support any efficacy conclusion.

Reported effects, cautions, and safety

What people in research-use communities report (anecdotal, not clinical evidence): The most common anecdotal reports are faster recovery from tendon, ligament, and joint injuries; less joint stiffness and pain; and improved digestive or gut symptoms. Some report faster wound healing, improved sleep, and reduced general inflammation. The most common complaints are injection-site redness and stinging, mild nausea or GI upset (especially with oral forms), and occasional fatigue or headache in the first week. Heart palpitations are rarely reported. All of these are unverified personal reports from research-use communities, not outcomes from controlled trials.

Safety cautions from the published literature:

• Human evidence is thin: almost everything known comes from rodents; large controlled human trials do not exist ^[2].
• A large share of foundational literature is from one group, limiting independent confirmation ^[2].
• BPC-157 is sold outside regulated channels; purity and identity of any given product are unverified.
• Strong pro-angiogenic activity (VEGFR2 pathway) raises a theoretical concern in the presence of active or undiagnosed cancer — tumors also depend on angiogenesis ^[4].
• Rodent data suggest modulation of serotonin systems; there is a theoretical, preclinical interaction concern with serotonin-affecting medicines ^[7].
• Long-term human safety data simply do not exist.
• WADA status: Prohibited in sport at all times under the S0 non-approved-substances category.

Where it fits in the research landscape

BPC-157 is the compound on this desk with the deepest animal-model record and the thinnest human evidence — a decades-long divergence that makes it one of the more interesting unresolved questions in the research-peptide space. The mechanism (angiogenesis, VEGFR2) is plausible and consistent across studies, the animal healing data are extensive, and yet the human trial program barely exists. A 2025 review treats it as investigational and urges caution ^[2].

It occupies a different research space from CJC-1295 (GH axis) and Retatrutide (metabolic), and a different mechanism space from GHK-Cu (matrix remodeling) and Thymosin Alpha-1 (immune modulation). What all of these share is a more-animal-than-human evidence base — but BPC-157 sits furthest from the clinical finish line.